Skip To Main Content
Yan-Ruide Li on Muck Rack

Yan-Ruide Li

As seen in: Nature, Frontiers, MDPI, Science Magazine, Cell Stem Cell, Cell Press, Cell Reports Medicine, Stem Cell Reports
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yan-Ruide

Contact Yan-Ruide, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Universal Nanovial Screening Enables Functional Discovery of Metabolite-Reactive T-Cell Receptors for Cancer Therapy Click to copy article link Article link copied!

|
By Citradewi Soemardy, Yan-Ruide Li, Yichen Zhu
| dx.doi.org
Open in Who Shared Issue with article?

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia

|
By Yan-Ruide Li, Xinyuan Shen, Yuning Chen, Yichen Zhu, Jie Huang, Caspian Oliai, Lili Yang
| Nature Verified
Abstract Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by the uncontrolled expansion of undifferentiated myeloid precursors in the bone marrow. Hypomethylating agents (HMAs) such as azacitidine and decitabine can reverse abnormal DNA methylation, promote leukemic cell differentiation, and enhance immune recognition, yet relapse and therapeutic resistance remain major challenges.
Open in Who Shared Issue with article?

Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors

|
By Yan-Ruide Li, Miao Li Verified, Yuning Chen, Houfu Leng, Yichen Zhu, Xinyuan Shen, Enbo Zhu, Jie Huang, Yu-Chen Wang, Abigail S. Krall, Heather Christofk, Aldons J. Lusis, Lili Yang, Duncan Croll
| Nature Verified
Abstract Chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapies have demonstrated remarkable efficacy in hematologic malignancies; however, their clinical performance in solid tumors remains limited due to suboptimal tumor infiltration, antigen heterogeneity, and immunosuppressive tumor microenvironments (TME).
Open in Who Shared Issue with article?
See all 22 articles